Engineering the gut microbiota to treat chronic diseases

Gut microbes play vital roles in host health and disease. A number of commensal bacteria have been used as vectors for genetic engineering to create living therapeutics. This review highlights recent advances in engineering gut bacteria for the treatment of chronic diseases such as metabolic disease...

Full description

Saved in:
Bibliographic Details
Published in:Applied microbiology and biotechnology 2020-09, Vol.104 (18), p.7657-7671
Main Authors: Dosoky, Noura S., May-Zhang, Linda S., Davies, Sean S.
Format: Article
Language:English
Subjects:
Analysis
Animal models
Animals
Atherosclerosis
Autoimmune diseases
Bacteria
Bacteria - genetics
Biomedical and Life Sciences
Biotechnology
Chronic Disease
Chronic diseases
Chronic illnesses
Gastrointestinal diseases
Gastrointestinal Microbiome
Gastrointestinal system
Genetic engineering
Genetic vectors
Genetically modified organisms
Homeopathy
Inflammation
Inflammatory Bowel Diseases
Intestinal microflora
Intestine
Life Sciences
Materia medica and therapeutics
Medical research
Medicine, Experimental
Metabolic disorders
Metabolites
Mice
Microbial Genetics and Genomics
Microbiology
Microbiota
Microbiota (Symbiotic organisms)
Mini-Review
Physiological aspects
Therapeutics
Tumors
Vectors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gut microbes play vital roles in host health and disease. A number of commensal bacteria have been used as vectors for genetic engineering to create living therapeutics. This review highlights recent advances in engineering gut bacteria for the treatment of chronic diseases such as metabolic diseases, cancer, inflammatory bowel diseases, and autoimmune disorders. Key points • Bacterial homing to tumors has been exploited to deliver therapeutics in mice models. • Engineered bacteria show promise in mouse models of metabolic diseases. • Few engineered bacterial treatments have advanced to clinical studies.
ISSN:0175-7598
1432-0614
DOI:10.1007/s00253-020-10771-0